CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project explores the role of the BRCA2 gene in the response of prostate cancer cells to radioligand therapy. By studying how BRCA2 deficiency affects treatment outcomes and immune response, the research aims to identify potential biomarkers for patient selection and improve therapeutic strategies.
Despite current advances in prostate cancer (PCa) treatment, 10 to 20% of PCa will evolve to a metastatic stage, where the overall survival is 14 months.
Radioligand therapy (RLT) is a new, promising treatment consisting in the injection of a radiolabelled vector.
In PCa, this therapy targets Prostate Specific Membrane Antigen, which is overexpressed on PCa cells compared to other tissues. RLT has been shown to increase the overall survival of patients in clinical trials, but in order to improve…
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
